Depression is fairly common among those with vision loss and a real risk for people with age-related macular degeneration. It’s natural to have an emotional response to vision loss, but clinical depression is a serious diagnosis. A study funded by the National Eye Institute showed that a type of rehabilitation therapy can cut this risk in half. .
Early results of a clinical trial indicate a drug currently used for multiple sclerosis (MS) may have long term benefits for those with dry age-related macular degeneration (AMD).
Earlier in the summer, we reported on the recruitment for a Phase 3 clinical trial of Fovista for wet macular degeneration. Fovista is being developed by Ophthotech, which just announced three expansion trials to begin soon.
We know that age is a large factor in developing age-related macular degeneration and that the older one gets, the higher the risk. Now, researchers in Germany have discovered evidence that AMD can actually start much earlier.
The standard treatment is for wet macular degeneration involves repeated injections into the eye. These can be very expensive, especially for someone without a secondary insurance. Lucentis and Eylea cost around $2000 per injection. The financial burden can be overwhelming.
The Patient Access Network (PAN) Foundation is dedicated to providing help and hope to underinsured patients who would otherwise be unable to afford high-cost specialty medications.